Amsterdam, May 15, 2017 – On June 16, Teva Pharmaceuticals Europe B.V. will host a webcast to discuss latest approaches to managing breakthrough pain in cancer patients. The webinar – ‘Shifting paradigms in breakthrough cancer pain (BTcP) management’ – will bring together a leading, international panel of oncologists, pains specialists, nurses and patient representatives to share their views on the state of European BTcP management & guidelines. The panel will also address BTcP from the oncologist’s versus pain specialist’s
On cancer pain and breakthrough cancer pain,
Also participating in the webcast are Dr. Frank Elsner, Vice Chair & Assitant Medical Director at the Department
Many barriers to effective pain control for cancer patients have been researched, including failure to diagnose breakthrough pain, an emphasis on cancer treatment over pain management, limited prioritisation of pain control in public health, as well as an absence of national policies on opioid use.2 Furthermore, awareness among care providers of BTcP treatment guidelines has been lacking.3 Roughly
The webcast, “Shifting paradigms in BTcP management” will take place on 16 June at 13:00 (CET)/ 12:00 (BST). For information on the webcast or to sign up, please visit www.beconown.com. Healthcare professionals, who are interested in further information on cancer pain and on the latest advances in the field, are also invited to join Teva’s LinkedIn group: ‘Driving advances in cancer pain management’ (www.linkedin.com/groups/8600759/profile).
Teva is among the top 15 global pharmaceutical companies globally, delivering high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Teva produces a leading innovative treatment for multiple sclerosis and has late-stage development programs for a range of disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions. With its European headquarters in Amsterdam, the Netherlands, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a broad range of products in nearly every therapeutic area. Teva draws on its specialty and generics capabilities to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com